Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.45 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30584811 | 0.83 | CA2 (0.52) | CA2ITGB3ITGA2BF2PLG | |
| SCHEMBL11681593 | 0.83 | CA2 (0.48) | CA2CAMK2AAKR1B1ITGB3ITGA2B | |
| SCHEMBL3086516 | 0.80 | CYP4F2 (0.54) | LMNAGAAKMT2AKDM4EALDH1A1 | |
| SCHEMBL21903097 | 0.80 | HDAC6 (0.43) | LMNAHTTKMT2AMEN1F2 | |
| SCHEMBL11681760 | 0.80 | NR1H4 (0.48) | CA2CAMK2AAKR1B1ITGB3ITGA2B | |
| SCHEMBL28501530 | 0.80 | HDAC1 (0.63) | CA2CAMK2ANR1H4EPHX2HSD17B10 | |
| SCHEMBL6393860 | 0.77 | HDAC6 (0.74) | CA2LMNAGAAKMT2AMEN1 | |
| SCHEMBL4403830 | 0.77 | TSHR (0.57) | CA2TSHRSRD5A2MEP1BALDH1A1 | |
| SCHEMBL3087853 | 0.76 | CYP4Z1 (0.54) | LMNATSHRHTTKMT2AMEN1 | |
| SCHEMBL7444750 | 0.76 | ALDH1A1 (0.47) | LMNAGAATSHRHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606548-B2 | Fungicidal oxadiazoles | FMC CORPORATION (US) | 2026-04-21 | — | — | US | disclosed |
| US-20240166638-A1 | FUNGICIDAL OXADIAZOLES | FMC CORP (US) | 2024-05-23 | — | — | US | disclosed |
| CN-118047729-A | Fungicidal oxadiazoles | FMC公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-118047771-A | Fungicidal oxadiazoles | FMC公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-110650956-B | Fungicidal oxadiazoles | FMC公司 | 2024-03-08 | — | — | CN | disclosed |
| EP-4262396-A1 | FUNGICIDAL OXADIAZOLES AND THEIR MIXTURES | FMC CORPORATION (US) | 2023-10-25 | — | — | EP | disclosed |
| CN-116634874-A | Fungicidal oxadiazoles and mixtures thereof | FMC公司 | 2023-08-22 | — | — | CN | disclosed |
| US-11708358-B2 | Fungicidal oxadiazoles | FMC CORPORATION (US) | 2023-07-25 | — | — | US | disclosed |
| WO-2022133114-A1 | FUNGICIDAL OXADIAZOLES AND THEIR MIXTURES | FMC CORPORATION (US) | 2022-06-23 | — | — | WO | disclosed |
| EP-3957636-A1 | FUNGICIDAL OXADIAZOLES | FMC Corporation (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20100063108-A1 | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-03-11 | — | — | US | disclosed |
| US-20100063108-A1 | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-03-11 | — | — | US | disclosed |
| EP-2125797-A1 | AMINO- PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-12-02 | — | — | EP | disclosed |
| EP-2069336-A1 | PYRIDIN-4-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-17 | — | — | EP | disclosed |
| EP-2069335-A1 | PYRIDIN-3-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008114157-A1 | AMINO- PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008029371-A1 | PYRIDIN-4-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008029371-A1 | PYRIDIN-4-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008029370-A1 | PYRIDIN-3-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008029370-A1 | PYRIDIN-3-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166638-A1 | FUNGICIDAL OXADIAZOLES | OXA1L, NOX1, TH | CA2 1403/4885CAMK2A 3738/4885AKR1B1 66/4885 |
| US-20100063108-A1 | Pyridin-4-yl derivatives as immunomodulating agents | CD4, FCGRT, IL2 | CA2 4484/4885CAMK2A 3446/4885AKR1B1 630/4885 |
| US-12606548-B2 | Fungicidal oxadiazoles | AOC2, AOC3, MT-CO3 | CA2 306/4885CAMK2A 4219/4885AKR1B1 1718/4885 |
| US-11708358-B2 | Fungicidal oxadiazoles | OXA1L, NOX1, TH | CA2 1403/4885CAMK2A 3738/4885AKR1B1 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.